Inspiro Medical is solely dedicated to developing a dry powder inhaler platform that delivers small molecule drugs to treat respiratory diseases. The Inspiromatic is the first active dry powder inhaler. It controls the delivery of the medication at a low inhalation flow rate, indicates to the user whether the medication has been properly inhaled and sounds a beeper once the dose has been delivered. Additionally, the Inspiromatic logs patient use data that physicians can track.
“We expect this innovative device to play a valuable role in the improvement of therapy for asthma, chronic obstructive pulmonary disease, cystic fibrosis and other respiratory diseases,” said Phillip Frost, MD, CEO and chairman of OPKO, in a news release.
More Articles on Device Companies:
Stryker Completes Acquisition of Berchtold Holding AG
Medtronic to Appeal Court’s Decision Banning Sale of CoreValve System
Enovate Medical to Relocate Headquarters
